Lesson 9 - Evolving Concepts in the Pathogenesis and Treatment of Pulmonary Arterial Hypertension

By John R. McArdle, MD, FCCP; and Terence K. Trow, MD, FCCP

Read/Print This Document
Poststudy Questions

Dr. McArdle is Co-Director, Yale Pulmonary Hypertension Program, Assistant Professor of Medicine, Section of Pulmonary and Critical Care Medicine; and Dr. Trow is Co-Director, Yale Pulmonary Hypertension Program, Assistant Professor of Medicine, Section of Pulmonary and Critical Care Medicine, Yale University School of Medicine, New Haven, CT.

Dr. McArdle has disclosed financial relationships with commercial parties. Grant information and company names appear as provided by the author.

Actelion – speaker bureau
Encysive Pharmaceuticals, Actelion – scientific advisory boards

Dr. Trow has disclosed financial relationships with commercial parties. Grant information and company names appear as provided by the author.

Actelion, Encysive Pharmaceuticals – consultant fees
Actelion – speaker bureau
Actelion – advisory committee

---

Lesson 10 - Toxin-Related Noncardiogenic Pulmonary Edema

By Walter H. Mullen, PharmD

Read/Print This Document
Poststudy Questions

Dr. Mullen is Assistant Clinical Professor of Pharmacy, University of California San Francisco, and Toxicology Management Specialist, California Poison Control System, San Francisco Division, San Francisco, CA.

Dr. Mullen has disclosed no significant relationships with the companies/organizations whose products or services may be discussed within this chapter.